Prof. Sibylle Loibl

Go Back

Medical Oncologist

  • German Breast Group GmbH
  • location Germany
Prof. Sibylle Loibl has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AstraZeneca, Amgen, Novartis, Pfizer and Roche. 

Programmes developed by Prof. Sibylle Loibl

other Other
Oncology 
The Role of DDR and PARP inhibition (PARPi) in Oncology – BluePrints

Experts
Dr Violeta Serra, Prof. Jonathan A. Ledermann, Prof. Eric Pujade-Lauraine, Prof. Simon Boulton, Dr Mark J. O'Connor, Prof. Charlie Gourley, Dr Judith Balmaña, Prof. Sibylle Loibl
  • download Downloadable
    Resources
  • clock MIN
  • calendar Sep 2021

This educational programme is supported by an Independent Educational Grant from AstraZeneca
Oncology 
Moving from PARP Inhibition to Targeting DNA Repair and DDR in Cancer Therapy

Experts
Dr Judith Balmaña, Dr Rebecca Dent, Prof. Simon Boulton, Prof. Sibylle Loibl, Prof. Eric Pujade-Lauraine, Prof. Charlie Gourley, Dr Violeta Serra, Prof. Jonathan A. Ledermann
  • download Downloadable
    Resources
  • clock 10 MIN
  • calendar Sep 2021

This educational programme is supported by an Independent Educational Grant from AstraZeneca